Podcasts about green templeton

Peggy Frith interviews Jim Holt, former Director of Clinical studies for Oxford Medical School, 1 June 2012. Topics discussed include: (00:00:41) university days at St. Andrews; (00:01:53) going to Canada to work at Kingston General Hospital; (00:03:31) returning to Oxford, Nuffield Professors of Medicine, overview of Oxford career; (00:06:43) interest in lymphoma; (00:08:17) differences between Canadian and British medicine in the 1960s; (00:09:22) experience of arriving and working in Oxford; (00:12:07) time as Director of Clinical studies, challenges and enjoyment; (00:18:36) success of Oxford clinical medical school, Green Templeton college, the Nuffield Foundation; (00:29:00) growth of Oxford Medical School; (00:36:45) Tingewick Society; (00:40:34) Holt family labrador trips to the medical wards in Oxford. Note the following sections of audio are redacted: 00:00:00-00:00:13; 00:18:04-00:18:33; 00:34:07-00:35:30.

Derek Hockaday interviews Julian Britton, surgeon and former Director of Clinical Studies for Oxford Medical School, 23 Jan 2019. Topics discussed include: (00:00:10) deciding to come to Oxford; (00:03:18) going to Newport as a senior registrar; (00:06:00) thoughts when first arriving at Oxford, surgeons, memories of Ted Maloney; (00:11:26) leaving the Nuffield Department of Surgery and applying for professorship; (00:12:34) research whilst in the Nuffield Department of Surgery and with the haematology department, Cardiff; (00:15:30) impressions of the Radcliffe Infirmary nursing and facilities when arriving from Newport; (00:19:04) time as Director of Clinical Studies at Oxford in 1983; (00:26:02) interest and training in keyhole surgery and endoscopic retrograde cholangiopancreatography; (00:32:24) liver surgery; (00:37:11) the development of ultrasound, use particularly with jaundiced patients; (00:41:13) nursing changes and the Salmon report; (00:42:22) medical administration changes; (00:52:23) private practice; (00:54:18) surgical departments, surgeon colleagues; (01:01:40) publications; (01:04:37) laparoscopic repair; (01:06:35) holidays and hobbies; (01:09:11) training up junior staff in surgeries; (01:11:06) Green Templeton college and The Radcliffe Committee, time as the Vice-Warden of the college; (01:17:30) portraits of John Walton; (01:22:20) final thoughts including changing opinion of arts subjects and how they help in medical career, Alex Gatherer, Peter Morris and David Weatherall; (01:33:25) grand rounds of endoscopic and laparoscopc surgeries. Note that the following sections of audio are redacted: 00:11:57-00:12:20; 01:18:06-01:18:25; 01:27:25-01:28:00; 01:31:04-01:32:45.

What should patients and clinicians make of uncertainty, risk and decision making in medical care? Dr Angela Coulter delivers a lecture at Green Templeton College as part of the Uncertainty series.

What should patients and clinicians make of uncertainty, risk and decision making in medical care? Dr Angela Coulter delivers a lecture at Green Templeton College as part of the Uncertainty series.

Dr Patterson will review the background to the pharmaceutical crisis and the different ways that companies are approaching the issues. The lecture will review both the research and development and business issues facing the industry and its investors. The Pharmaceutical industry has been through a period of unprecedented growth in the last three decades, fuelled by the advances in biomedical science and an increasingly affluent Western Society. Looking forward, the picture is less rosy with reduced research and development productivity coupled with increasing pre-registration data demands from regulators and burgeoning costs. Taken together with major products losing patent protection and the need for health care costs to be kept under control, the current business model is under threat. Dr Patterson will review the background to the crisis and the different ways that companies are approaching the issues. The lecture will review both the research and development and business issues facing the industry and its investors.

Dr Patterson will review the background to the pharmaceutical crisis and the different ways that companies are approaching the issues. The lecture will review both the research and development and business issues facing the industry and its investors. The Pharmaceutical industry has been through a period of unprecedented growth in the last three decades, fuelled by the advances in biomedical science and an increasingly affluent Western Society. Looking forward, the picture is less rosy with reduced research and development productivity coupled with increasing pre-registration data demands from regulators and burgeoning costs. Taken together with major products losing patent protection and the need for health care costs to be kept under control, the current business model is under threat. Dr Patterson will review the background to the crisis and the different ways that companies are approaching the issues. The lecture will review both the research and development and business issues facing the industry and its investors.

The third Green Templeton Lecture 2009 explores how, by harnessing innovation to meet unmet medical needs, pharma companies can deliver significant value to patients, payers and shareholders. The Green Templeton Lectures 2009 explored the theme 'Addicted to Big Pharma? Reconciling business, medical and ethical needs' in a series of four lectures looking at the pharmaceutical industry past, present and future. This lecture was delivered by Patrick Vallance (Head of Drug Discovery; GlaxoSmithKline) Philip Bloomer (Director of Campaigns; Oxfam).

The third Green Templeton Lecture 2009 explores how, by harnessing innovation to meet unmet medical needs, pharma companies can deliver significant value to patients, payers and shareholders. The Green Templeton Lectures 2009 explored the theme 'Addicted to Big Pharma? Reconciling business, medical and ethical needs' in a series of four lectures looking at the pharmaceutical industry past, present and future. This third lecture was delivered by Patrick Vallance (Head of Drug Discovery; GlaxoSmithKline) Philip Bloomer (Director of Campaigns; Oxfam)

This lecture will explore, from a historical perspective, the relationship between an emerging pharmaceutical industry, the establishment of drug regulatory authorities, and - most recently - the development of health technology assessment.

This lecture will explore, from a historical perspective, the relationship between an emerging pharmaceutical industry, the establishment of drug regulatory authorities, and - most recently - the development of health technology assessment.

Tilli Tansey, Professor of History of Modern Medical Sciences, University College London traces the evolution of the modern pharmaceutical industry from the mid nineteenth century to the final decades of the twentieth century. The strong focus on British companies is not exclusive, and a large cast of characters including manufacturers, doctors, scientists and patients are considered. Several themes are explored, including the role of innovation in relation to production technology, marketing and advertising, and in particular in pharmaceutical research and drug discovery. The impact of legislation is examined with respect to animal experimentation, standardisation and drug safety. These changes will be discussed against a background of scientific advances, clinical developments and patient expectations.

Tilli Tansey, Professor of History of Modern Medical Sciences, University College London traces the evolution of the modern pharmaceutical industry from the mid nineteenth century to the final decades of the twentieth century. The strong focus on British companies is not exclusive, and a large cast of characters including manufacturers, doctors, scientists and patients are considered. Several themes are explored, including the role of innovation in relation to production technology, marketing and advertising, and in particular in pharmaceutical research and drug discovery. The impact of legislation is examined with respect to animal experimentation, standardisation and drug safety. These changes will be discussed against a background of scientific advances, clinical developments and patient expectations.

Lord Walton of Detchant gave the 12th annual Alan Emery Lecture at Green Templeton College, Oxford on 5 June 2008. His lecture was entitled 'A Myologist in the House'. After a brief early history of research into Duchenne muscular dystrophy, or Meryon's disease, Lord Walton concluded with an excellent summary of current progress in cybrid development and the future possibilities of stem cell therapy.